Literature DB >> 1985164

Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study.

J Ochs1, R Mulhern, D Fairclough, L Parvey, J Whitaker, L Ch'ien, A Mauer, J Simone.   

Abstract

We prospectively compared neuropsychologic functioning and clinical indicators of neurotoxicity in 49 consecutive childhood leukemia patients in long-term continuous complete remission (CR) who had received two different regimens of CNS prophylaxis by random assignment. Twenty-three patients were treated with 1,800 cGy cranial radiation and intrathecal methotrexate (RT group) and 26 with parenteral methotrexate only (MTX group). Over half of the RT group had somnolence syndrome, and four developed cerebral calcifications late in their clinical course. Abnormal electroencephalograms (EEGs) were seen in 15 patients in the MTX group, and six had early, transient white-matter hypodensities apparent on computed tomographic (CT) scans. Mean scores on standard tests of intelligence and academic achievement, administered after remission induction and again at a median of 6 years after treatment cessation, did not differ significantly between the two groups. However, statistically significant decreases in overall and verbal intelligence quotients (IQs) and in arithmetic achievement were found within both treatment groups. Sixteen of 26 in the MTX group and 14 of the 23 in the RT group had clinically important decreases (greater than or equal to 15 points) on one or more neuropsychologic measures. These changes did not correlate with findings on CT scans, EEGs, or other clinical signs of neurotoxicity. We conclude that 1,800 cGy cranial radiation and parenteral methotrexate, as used in this study, are associated with comparable decreases in neuropsychologic function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985164     DOI: 10.1200/JCO.1991.9.1.145

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  33 in total

Review 1.  Advances in the assessment of childhood brain tumors and treatment-related sequelae.

Authors:  Katherine E Warren
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

Review 2.  Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Authors:  Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

3.  Reduced frontal white matter volume in long-term childhood leukemia survivors: a voxel-based morphometry study.

Authors:  M E Carey; M W Haut; S L Reminger; J J Hutter; R Theilmann; K L Kaemingk
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-09       Impact factor: 3.825

4.  Long-term decline in intelligence among adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiation.

Authors:  Kevin R Krull; Nan Zhang; Aimee Santucci; Deo Kumar Srivastava; Matthew J Krasin; Larry E Kun; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson; Gregory T Armstrong
Journal:  Blood       Date:  2013-06-06       Impact factor: 22.113

Review 5.  [White matter alterations after chemotherapy and radiation].

Authors:  A Simgen
Journal:  Radiologe       Date:  2018-12       Impact factor: 0.635

Review 6.  Central nervous system-directed therapy in the treatment of childhood acute lymphoblastic leukemia and studies of neurobehavioral outcome: Children's Cancer Group trials.

Authors:  Thomas A Kaleita
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

7.  Milestones in the curability of pediatric cancers.

Authors:  Melissa M Hudson; Michael P Link; Joseph V Simone
Journal:  J Clin Oncol       Date:  2014-04-14       Impact factor: 44.544

8.  Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia.

Authors:  Nina S Kadan-Lottick; Pim Brouwers; David Breiger; Thomas Kaleita; James Dziura; Veronika Northrup; Lu Chen; Megan Nicoletti; Bruce Bostrom; Linda Stork; Joseph P Neglia
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

9.  Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study.

Authors:  Kevin R Krull; Tara M Brinkman; Chenghong Li; Gregory T Armstrong; Kirsten K Ness; Deo Kumar Srivastava; James G Gurney; Cara Kimberg; Matthew J Krasin; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2013-11-04       Impact factor: 44.544

Review 10.  Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.

Authors:  Carla C P Verstappen; Jan J Heimans; Klaas Hoekman; Tjeerd J Postma
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.